33336172|t|Bone marrow mesenchymal stem cell transplantation downregulates plasma level and the microglia expression of transforming growth factor beta1 in the acute phase of cerebral cortex ischemia.
33336172|a|BACKGROUND: Both bone marrow mesenchymal stem cell (BM-MSC) and transforming growth factor-beta1 (TGF-beta1) have a strong anti-inflammatory capacity in stroke. But their relationship has not been well addressed. In this study, we investigated how intravenous BM-MSC transplantation in rats effected the expression of TGF-beta1 48 h post cerebral ischemia, and we analyzed the main cells that produce TGF-beta1. METHODS: We used a distal middle cerebral artery occlusion (dMCAO) model in twenty Sprague-Dawley (SD) rats. The rats were randomly divided into two groups: the ischemic control group and the postischemic BM-MSC transplantation group. One hour after the dMCAO model was established, the rats were injected in the tail vein with either 1 ml saline or 1 x 106 BM-MSCs suspended in 1 ml saline. ELISAs were used to detect TGF-beta1 content in the brain infarct core area, striatum and the plasma at 48 h after cerebral infarction. Immunofluorescent staining of brain tissue sections for TGF-beta1, Iba-1, CD68 and NeuN was performed to determine the number and the proportion of double stained cells and to detect possible TGF-beta1 producing cells in the brain tissue. RESULTS: Forty-eight hours after ischemia, the TGF-beta1 content in the infarcted area of the BM-MSC transplantation group (23.94 +- 4.48 pg/ml) was significantly lower than it was in the ischemic control group (34.18 +- 4.32 pg/ml) (F = 13.534, P = 0.006). The TGF-beta1 content in the rat plasma in the BM-MSC transplantation group (75.91 +- 12.53 pg/ml) was significantly lower than it was in the ischemic control group (131.18 +- 16.07 pg/ml) (F = 36.779, P = 0.0002), suggesting that after transplantation of BM-MSCs, TGF-beta1 levels in the plasma decreased, but there was no significant change in the striatum area. Immunofluorescence staining showed that the total number of nucleated cells (1037.67 +- 222.16 cells/mm2) in the infarcted area after transplantation was significantly higher than that in the ischemic control group (391.67 +- 69.50 cells/mm2) (F = 92.421, P < 0.01); the number of TGF-beta1+ cells after transplantation (35.00 +- 13.66 cells/mm2) was significantly reduced in comparison to that in the ischemic control group (72.33 +- 32.08 cells/mm2) (F = 37.680, P < 0.01). The number of TGF-beta1+/Iba-1+ microglia cells in the transplantation group (3.67 +- 3.17 cells/mm2) was significantly reduced in comparison to that of the ischemic control group (13.67 +- 5.52 cells/mm2) (F = 29.641, P < 0.01). The proportion of TGF-beta1+/Iba-1+ microglia cells out of all Iba-1+ microglia cells after transplantation (4.38 +- 3.18%) was significantly decreased compared with that in the ischemic control group (12.81 +- 4.86%) (F = 28.125, P < 0.01). CONCLUSIONS: Iba-1+ microglia is one of the main cell types that express TGF-beta1. Intravenous transplantation of BM-MSCs does not cooperate with TGF-beta1+ cells in immune-regulation, but reduces the TGF-beta1 content in the infarcted area and in the plasma at 48 h after cerebral infarction.
33336172	109	141	transforming growth factor beta1	Gene	59086
33336172	164	188	cerebral cortex ischemia	Disease	MESH:D002545
33336172	242	244	BM	CellLine	CVCL:E481
33336172	254	286	transforming growth factor-beta1	Gene	59086
33336172	288	297	TGF-beta1	Gene	59086
33336172	318	330	inflammatory	Disease	MESH:D007249
33336172	343	349	stroke	Disease	MESH:D020521
33336172	450	452	BM	CellLine	CVCL:E481
33336172	476	480	rats	Species	10116
33336172	508	517	TGF-beta1	Gene	59086
33336172	528	545	cerebral ischemia	Disease	MESH:D002545
33336172	591	600	TGF-beta1	Gene	59086
33336172	621	660	distal middle cerebral artery occlusion	Disease	MESH:D020244
33336172	662	667	dMCAO	Disease	MESH:D020244
33336172	705	709	rats	Species	10116
33336172	715	719	rats	Species	10116
33336172	763	771	ischemic	Disease	MESH:D002545
33336172	807	809	BM	CellLine	CVCL:E481
33336172	856	861	dMCAO	Disease	MESH:D020244
33336172	889	893	rats	Species	10116
33336172	960	962	BM	CellLine	CVCL:E481
33336172	1021	1030	TGF-beta1	Gene	59086
33336172	1046	1059	brain infarct	Disease	MESH:D020520
33336172	1109	1128	cerebral infarction	Disease	MESH:D002544
33336172	1186	1195	TGF-beta1	Gene	59086
33336172	1197	1202	Iba-1	Gene	29427
33336172	1204	1208	CD68	Gene	287435
33336172	1213	1217	NeuN	Gene	287847
33336172	1322	1331	TGF-beta1	Gene	59086
33336172	1402	1410	ischemia	Disease	MESH:D007511
33336172	1416	1425	TGF-beta1	Gene	59086
33336172	1441	1450	infarcted	Disease	MESH:D007238
33336172	1463	1465	BM	CellLine	CVCL:E481
33336172	1557	1565	ischemic	Disease	MESH:D002545
33336172	1631	1640	TGF-beta1	Gene	59086
33336172	1656	1659	rat	Species	10116
33336172	1674	1676	BM	CellLine	CVCL:E481
33336172	1769	1777	ischemic	Disease	MESH:D002545
33336172	1883	1885	BM	CellLine	CVCL:E481
33336172	1892	1901	TGF-beta1	Gene	59086
33336172	2105	2114	infarcted	Disease	MESH:D007238
33336172	2184	2192	ischemic	Disease	MESH:D002545
33336172	2273	2282	TGF-beta1	Gene	59086
33336172	2394	2402	ischemic	Disease	MESH:D002545
33336172	2482	2491	TGF-beta1	Gene	59086
33336172	2493	2498	Iba-1	Gene	29427
33336172	2625	2633	ischemic	Disease	MESH:D002545
33336172	2716	2725	TGF-beta1	Gene	59086
33336172	2727	2732	Iba-1	Gene	29427
33336172	2761	2766	Iba-1	Gene	29427
33336172	2876	2884	ischemic	Disease	MESH:D002545
33336172	2953	2958	Iba-1	Gene	29427
33336172	3013	3022	TGF-beta1	Gene	59086
33336172	3055	3057	BM	CellLine	CVCL:E481
33336172	3087	3096	TGF-beta1	Gene	59086
33336172	3142	3151	TGF-beta1	Gene	59086
33336172	3167	3176	infarcted	Disease	MESH:D007238
33336172	3214	3233	cerebral infarction	Disease	MESH:D002544
33336172	Negative_Correlation	MESH:D020521	59086
33336172	Negative_Correlation	MESH:D007249	59086
33336172	Association	MESH:D002545	59086
33336172	Association	MESH:D002544	59086

